Guardant Health (NASDAQ:GH) Director Sells $11,131.36 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of Guardant Health stock in a transaction on Monday, May 18th. The stock was sold at an average price of $95.96, for a total transaction of $11,131.36. Following the completion of the transaction, the director directly owned 8,662 shares of the company’s stock, valued at $831,205.52. The trade was a 1.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $84.83, for a total transaction of $9,840.28.
• On Wednesday, March 18th, Musa Tariq sold 348 shares of Guardant Health stock. The shares were sold at an average price of $88.09, for a total transaction of $30,655.32.

Guardant Health Stock Up 2.6%

GH traded up $2.53 on Tuesday, hitting $98.19. The company had a trading volume of 1,543,322 shares, compared to its average volume of 2,029,689. The business’s fifty day simple moving average is $89.36 and its 200 day simple moving average is $98.28. Guardant Health, Inc. has a 12-month low of $36.36 and a 12-month high of $120.74. The company has a market cap of $13.02 billion, a PE ratio of -28.96 and a beta of 1.48.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. Guardant Health’s revenue for the quarter was up 39.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.62) EPS. On average, analysts anticipate that Guardant Health, Inc. will post -2.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $135.00 price objective on shares of Guardant Health in a research note on Tuesday, May 12th. Wells Fargo & Company lifted their price objective on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Robert W. Baird assumed coverage on shares of Guardant Health in a research note on Tuesday, February 17th. They set an “outperform” rating and a $120.00 price objective for the company. BTIG Research lifted their price objective on shares of Guardant Health from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Finally, Evercore set a $110.00 price objective on shares of Guardant Health in a research note on Friday, February 20th. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $129.42.

Institutional Trading of Guardant Health

A number of large investors have recently made changes to their positions in the stock. V Square Quantitative Management LLC bought a new stake in shares of Guardant Health in the fourth quarter valued at about $27,000. Chesapeake Asset Management LLC purchased a new stake in Guardant Health in the fourth quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Guardant Health in the fourth quarter worth about $31,000. Elyxium Wealth LLC bought a new position in Guardant Health during the 4th quarter worth about $35,000. Finally, Parallel Advisors LLC grew its holdings in Guardant Health by 164.7% during the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after acquiring an additional 219 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.